ATE337004T1 - Verwendung von mangafodipir zur behandlung der hepatozellularen insuffizienz - Google Patents
Verwendung von mangafodipir zur behandlung der hepatozellularen insuffizienzInfo
- Publication number
- ATE337004T1 ATE337004T1 AT02735506T AT02735506T ATE337004T1 AT E337004 T1 ATE337004 T1 AT E337004T1 AT 02735506 T AT02735506 T AT 02735506T AT 02735506 T AT02735506 T AT 02735506T AT E337004 T1 ATE337004 T1 AT E337004T1
- Authority
- AT
- Austria
- Prior art keywords
- mangafodipir
- treat hepatocellular
- hepatocellular insufficiency
- insufficiency
- treat
- Prior art date
Links
- QDQFSBKXQQZVTB-UHFFFAOYSA-L 2-[2-[carboxylatomethyl-[[2-methyl-3-oxido-5-(phosphonatooxymethyl)pyridin-4-yl]methyl]amino]ethyl-[[2-methyl-3-oxido-5-(phosphonatooxymethyl)pyridin-4-yl]methyl]amino]acetate;hydron;manganese(2+) Chemical compound [H+].[H+].[H+].[H+].[H+].[H+].[Mn+2].CC1=NC=C(COP([O-])([O-])=O)C(CN(CCN(CC([O-])=O)CC=2C(=C(C)N=CC=2COP([O-])([O-])=O)[O-])CC([O-])=O)=C1[O-] QDQFSBKXQQZVTB-UHFFFAOYSA-L 0.000 title abstract 2
- 229960002382 mangafodipir Drugs 0.000 title abstract 2
- 238000009109 curative therapy Methods 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0105606A FR2823977B1 (fr) | 2001-04-26 | 2001-04-26 | Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE337004T1 true ATE337004T1 (de) | 2006-09-15 |
Family
ID=8862711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02735506T ATE337004T1 (de) | 2001-04-26 | 2002-04-26 | Verwendung von mangafodipir zur behandlung der hepatozellularen insuffizienz |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7351722B2 (de) |
| EP (1) | EP1381364B1 (de) |
| JP (1) | JP4371197B2 (de) |
| AT (1) | ATE337004T1 (de) |
| CA (1) | CA2443838A1 (de) |
| DE (1) | DE60214152T2 (de) |
| ES (1) | ES2271265T3 (de) |
| FR (1) | FR2823977B1 (de) |
| PT (1) | PT1381364E (de) |
| WO (1) | WO2002087579A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2863892B1 (fr) * | 2003-12-18 | 2007-05-11 | Univ Paris Descartes | Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux |
| KR101678865B1 (ko) | 2007-12-14 | 2016-11-23 | 플레드파르마 에이비 | 암의 치료에 사용하기 위한 화합물들 |
| CN105688215A (zh) * | 2009-07-06 | 2016-06-22 | 普莱制药公司 | 利用锰配合物化合物与所述化合物之非锰配合物形式的组合的药物组合物和治疗方法 |
| CN107353313B (zh) | 2012-01-05 | 2019-04-09 | 普莱制药公司 | 新化学实体钙锰福地吡和其他混合金属配合物、制备方法、组合物以及治疗方法 |
| EP3842040B1 (de) * | 2016-01-11 | 2022-03-09 | Egetis Therapeutics AB | Verfahren und formulierungen zur behandlung und/oder zum schutz gegen akute leberinsuffizienz und andere hepatotoxische zustände |
| KR20190085967A (ko) | 2016-11-14 | 2019-07-19 | 칼슨-튜너 인베스트 에이에스 | 화학요법으로-유도된 psn을 예방 및 치료하기 위한 비-전이 금속 배위된 디피리독실 화합물의 용도 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9613182D0 (en) * | 1996-06-24 | 1996-08-28 | Nycomed Imaging As | Method |
| GB9727224D0 (en) * | 1997-12-23 | 1998-02-25 | Nycomed Imaging As | Method |
-
2001
- 2001-04-26 FR FR0105606A patent/FR2823977B1/fr not_active Expired - Fee Related
-
2002
- 2002-04-26 EP EP02735506A patent/EP1381364B1/de not_active Expired - Lifetime
- 2002-04-26 PT PT02735506T patent/PT1381364E/pt unknown
- 2002-04-26 ES ES02735506T patent/ES2271265T3/es not_active Expired - Lifetime
- 2002-04-26 US US10/475,555 patent/US7351722B2/en not_active Expired - Fee Related
- 2002-04-26 AT AT02735506T patent/ATE337004T1/de not_active IP Right Cessation
- 2002-04-26 CA CA002443838A patent/CA2443838A1/fr not_active Abandoned
- 2002-04-26 JP JP2002584924A patent/JP4371197B2/ja not_active Expired - Fee Related
- 2002-04-26 WO PCT/FR2002/001457 patent/WO2002087579A1/fr not_active Ceased
- 2002-04-26 DE DE60214152T patent/DE60214152T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US7351722B2 (en) | 2008-04-01 |
| EP1381364B1 (de) | 2006-08-23 |
| CA2443838A1 (fr) | 2002-11-07 |
| PT1381364E (pt) | 2007-01-31 |
| JP4371197B2 (ja) | 2009-11-25 |
| ES2271265T3 (es) | 2007-04-16 |
| DE60214152D1 (de) | 2006-10-05 |
| WO2002087579A1 (fr) | 2002-11-07 |
| JP2004526792A (ja) | 2004-09-02 |
| EP1381364A1 (de) | 2004-01-21 |
| FR2823977B1 (fr) | 2006-12-01 |
| US20040142907A1 (en) | 2004-07-22 |
| FR2823977A1 (fr) | 2002-10-31 |
| DE60214152T2 (de) | 2007-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE451921T1 (de) | Phenylindole zur behandlung von hiv | |
| ATE380548T1 (de) | Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie | |
| ATE417602T1 (de) | Mittel zur behandlung von erkrankungen der speiseröhre | |
| ATE428413T1 (de) | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen | |
| ATE292134T1 (de) | Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien | |
| ATE414512T1 (de) | Kombinationstherapie zur behandlung von krebs | |
| DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
| DE60129330D1 (de) | Verwendung von cox-2 inhibitoren als immunostimulantien zur behandlung von hiv oder aids | |
| DE60130661D1 (de) | Verwendung der 13-cis retinsäure zur behandlung von emphysemen | |
| ATE353667T1 (de) | Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges | |
| EA200702212A1 (ru) | Способ лечения или профилактики разрушения кости или остеопороза | |
| ATE337004T1 (de) | Verwendung von mangafodipir zur behandlung der hepatozellularen insuffizienz | |
| ATE361071T1 (de) | Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie | |
| ATE380554T1 (de) | Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie | |
| ATE264101T1 (de) | Verwendung von thioamidoxazolidinonen zur behandlung von knochenresorption und osteoporose | |
| DE60223707D1 (de) | Calcium-l-threonat zur behandlung von knochenfrakturen | |
| DE60217653D1 (de) | Verwendung von melatonin zur behandlung der mit konzentrationsschwäche einhergehenden hyperaktivität | |
| ATE291921T1 (de) | Verwendung von bisphosphonaten zur behandlung von osteogenese imperfecta | |
| DE60213365D1 (de) | Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen | |
| ATE404203T1 (de) | Verwendung von desoxypeganin zur behandlung der klinischen depression | |
| ATE303151T1 (de) | Verwendung von mntbap zur behandlung von hepatischer insuffizienz | |
| ATE302009T1 (de) | Ubichinon qn zur behandlung von migräneschmerzen | |
| DE69904297D1 (de) | Neue verwendung von ropivacain zur schmerzbehandlung | |
| ATE291434T1 (de) | Verwendung von angiotensin zur behandlung von krebsmetastasierung | |
| DE10193322D2 (de) | Verwendung von Protonenpumpen-Hemmern zur Behandlung von Erkrankungen des Bewegungsapparates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1381364 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |